Company: ZVRA
Filing Date: 2025-05-08
Form Type: DEFA14A
Source: 0001193125-25-115961
Chunk: 7

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-08
Form: DEFA14A
Chunk 7
---
 trial of celiprolol Optimizing Pipeline to Invest in Highest-Return Opportunities In 2024, your Board and management team conducted a data-driven review of the pipeline to ensure we are investing in Zevra’s most promising, highest return opportunities KP1077 Maximizing value FDA and Zevra agreed on Phase 3 trial design; a single pivotal study with confirmatory evidence may support New Drug Application (NDA) submission Exploring strategic alternatives to maximize KP1077’s value

3 Our Refreshed Board Oversees a Purpose-Built Management Team

April 2024 Completed Strategic Debt Restructuring Bolstered Zevra’s balance sheet by restructuring our debt, using a new credit facility provided by premier biotech investors Zevra’s Board Has Strengthened the Company’s Corporate Foundation Disciplined approach to capital allocation has strengthened balance sheet and created significant financial flexibility for the Company as we advance Zevra’s transformation into a global commercial rare disease leader September 2024 Obtained PRV – Later Sold for $150M MIPLYFFA approval led to FDA awarding us a Rare Pediatric Disease PRV; we sold the PRV for $150 million in April 2025, providing non-dilutive capital to fuel our commercial ramp-up of MIPLYFFA and OLPRUVA We have ample resources and financial flexibility to execute on our strategy independent of the capital markets

Neil F. McFarlane Chief Executive Officer and President Alvin Shih, M.D. Director Thomas D. Anderson Director Douglas W. Calder Director Tamara A. Favorito Director Wendy L. Dixon, PH.D. Director Corey M. Watton Director John B. Bode Director 7 of 8 directors joined since 2023 7 of 8 directors are independent Proven, experienced public company leaders Deep scientific, commercial, regulatory, and financial expertise in a complex and specialized landscape Shares and oversees management’s long-term vision of delivering breakthrough therapies to patients with critical unmet needs Refreshed Board Has the Right Talent and Expertise to Support Zevra’s Continued Growth Our Refreshed Board has a Track Record of Delivering Outstanding Results Directors previously nominated by Mangless

DIRECTOR PUBLIC CO. DRUG DEVELOPMENT LIFE SCIENCES INDUSTRY FINANCIAL COMMERCIALIZATION / OPERATIONAL MARKETING Neil F. McFarlane President, CEO, and Director since October 2023 P P P P P P Wendy L. Dixon, Ph.D. Director since April 2023, Audit Committee P P P P